CDK19 and prostate cancer: We also generated derivatives of 22Rv1 prostate cancer cells (which overexpress CDK19 relative to CDK8) with the knockout of CDK8 and CDK19, individually and in combination (dKO), and analyzed STAT1 S727 phosphorylation with and without IFNγ treatment (Figure 7I).